Still hoping to offload a block of shares on a near-term run up before the dilutive financing vehicle comes to town. Good luck getting back over $1 when there's over 250 million shares sitting out there.

$20 is outrageous. Come on. Throwing around BS projections is just irresponsible. Besides smart $$ only cares about biosynthesis. The market for EB is minuscule. No one will be laying down big $$ at a PH2 announcement in the absence of a commercial path for biosynthesis. If biosynthesis is not online this company has nothing more than a mildly interesting drug pipeline. If ocular was entering trials smart $$ would be much more intrigued, but that's not even coming online until late '21.

INM-755 will do absolutely nothing for the share price and I'd put $$ on this wager

Just waiting until Friday to hear what new delays, or hurdles, or misses, will be plaguing this company

I don't understand the strategy in Mancini making 12 small block purchases over a 2 wk period. It's trading at pennies and you sold your commons last year for about 8X your current levels of buys. Why not buy a single block at your new target and be done with it?

It really just keeps getting worse and worse for this team. Consistent delays to pipeline programs, hitting a wall with biosynthesis, not a single patent approved and odds are getting worse as the EB patent pull if confirmed will impact Q4 PH1 filing.

Of course they are concerned. You don't go looking for $$ when you're broke so they hired Mr. Colwill to start making financing inroads now. Problem is you're faced w/shitty options when attempting a fresh round of financing and the SP is on a fire sale. I see them as being in a real pickle unless they have something of value about to drop. They are hitting more hurdles than achievements in biosynthesis so don't expect a jaw dropping announcement on that front any time soon.

Teewinot? If this is still an InMed forum people should be much more concerned about the state of InMed's affairs than their peers that are out there making bigger moves.

Why would anyone with a working brain be so excited about Mancini's recent purchases? Mancini sold just under 200k shares last year at an average share price of 1.69. She made a ton and now she's rebuying at a steep discount when most sitting around are holding her bag. Smart folks see another pump coming and should at minimum skim their holdings and do like Mancini. Ride the pump and dump.

Finally the sage Tim has something honest to say. Let's all have a "little reality check". Finally something some of us can agree on. Coming from the same person who celebrated a $20/SP target in February. The same person that provided no legitimacy to the "competition". Same person that used copious amounts of napkin math to prove his "theory" on the pricing and fantasy market of the minor cannabinoids.

Now our beloved Tim is finally having the little reality check that he's so desperately needed. The yeasty boys have issued patents and are driving towards a path of revenue generation which bodes well for both the companies and their stakeholders. More importantly a path of near-term revenue on a less restrictive model for CBD, THC, CBN, etc biosynthetic production.

InMed on the other hand is pursuing the minors which have no mature market, no established valuations, limited customer base (for now pharma research only), and a massively regulatory headache given the limited data that exists on their toxicology. This also on top of the fact that they are first a pharmaceutical company focused on a pipeline that changes every few yrs and w/a current top candidate that affects less children at birth globally than people being struck by lightning.

Cliff's note version of this thesis, if you're an investor and not a glossy eyed sideline admirer, put your $ to work on the publicly traded biosynthetic options that are focused on near-term revenue generation.

See purchase orders? This isn't a congressional hearing dude. Just say it out loud. Teewinot was first to commercialize their tech, first to market, and EA was full of shit.

The only thing noteworthly is biosynthetic leader Teewinot out proving their biosynthetic process and going commercial this week. This is the important news in this space worth paying attention to.

Interesting. I thought the 25k shares were an open market purchase of commons. He was just optioned a million why the hell even go through the effort of granting him 25k shares of commons? Very strange.

Glad you brought this up. Is it not hilarious that Bruce was granted a million options as part of his hiring package, yet people jump for joy that this millionaire spent a whopping $6500 buying commons in the past couple of wks.

It really makes for good comedy over there. Unfortunately in the real world share prices don't move based on unsubstantiated pumping. If they did we'd all be in great shape. At this point it's looking more and more like 2022 will be their transformative year.

He's no one. Just a random guy that floats incredibly off the mark price targets but has amassed a following from those that haven't got a clue in what they're doing so they grab the pant leg tightly.

Couple things. First, HB where is the data from the NRC regarding the CDMO? I've seen this referred to a couple of times recently, but don't have the source.

Also, I agree w/Steve regarding the timing of EA's common share liquidation. I find it incredibly poor taste as a CEO to dump his core, non option, position shortly after closing a rather large bought deal financing pkg. Legal sure, but it definitely sends the wrong message to financing partners.

Lastly, the best buy recently has been GW Pharma <$120/SP. It fell hard after a BS short hit piece on them and this has the best near-term trajectory. Landed a nice block at $106 felt like I won the day.

Fact is InMed has been working glaucoma for over 6 yrs and even today it's not targeted to hit the clinic until late '21. EB is targeted to hit the clinic this yr (assuming no addtl delays) but from a revenue generation standpoint it's not going to attract much attention. More people get struck by lightning each yr than those born w/EB. In the pipeline the $$ is in glaucoma.

Even more concerning is they're running into roadblocks w/biosynthesis. Who knows if they'll crack this nut and even if they do can they do it in a cost effective model w/pharma grade purity. Maybe, maybe not. Also, will they ever get a single patent? They continuously talk about their IP. What IP? You have patent filings and nothing more. EA is a magician at kicking the can down the road. He slightly tweaks little words or phrases in the forecast and presentations to give the impression they are mtg critical milestones while many just keep being pushed to the right.

Anyone else find it rather curious that 8 Cap, the purchaser of InMed's '18 bought deal offering, has a buy rating (near $5) on their competitor Willow Biosciences but absolutely no buy rating for InMed? Alta Corp also initiated a $5 buy rating on Willow. Many don't have confidence in InMed's execution.

At no point does Hsu state that they are considering a pivot to yeast. We can make various assumptions on what the "alternative approach" may be, but it does not necessarily indicate moving away from bacteria. It could be an alternative process w/the bacterial host in which expresses the proteins more effectively. What I do agree w/you is that IF it is a yeast based model it will likely be my cue to depart this investment. Between Teewinot, Librede, Willow, etc this area is overly crowded w/both patent locks and w/seasoned teams having a head start.

After the call I have the hurry along folks...nothing to see here feeling. Hsu commented that they have hit a ceiling w/their host (e coli) and exploring a second path. Hsu even gave credence to yeast in the response. Wow. Call it what you want I call it a dead end in scaling up. EA laughed at the question about exercising warrants. He has no confidence in them being @ 1.25 by June '20. Formulations have changed over and over for their lead pipeline candidates and no trials on the $ maker for glaucoma until late in '21.

This will likely be back in the teens by early October

As usual I see no major catalysts in the Sept presentation slide deck. Biosyn appears to be "on track" for now which could change tomorrow. Don't look any closer to naming the downstream CDMO partners (2 of them), glaucoma is still further out than most expected to see w/more secret unidentified partners and entering the clinic for EB is broken into a 3 step process that goes beyond 2H19 into '20. Another downer is they won't even be supplying their own cannabinoid formulation for the ~30 healthy patients taking part in EB PH1. While it's known they're not on a path for commercial scale biosynthesis manuf until 2H20, it is unfortunate that they are not even able to supply a low batch formulation in-house to support trials.

Come on they've been talking about the glaucoma partnerships since 2015. And Sazdanoff is on like 10 advisory boards. Hell of a revenue stream for her.

Well at least we'll know in just one short week if this company is truly on schedule to deliver the goodies or will it be just another one of many slippages to the drug delivery and biosynthetics programs. They surely are excelling in the area of attrition. Not a confidence builder to see the Bott resignation.

A big 100k block waiting on the buy side @ .25

Hard to say as it never executed before the bell. That's quite a large block given that some recent wks barely saw over 200k total volume for the day. I think today's session will be a key indicator of continued momentum or a retrace back to Tues lows. Will volume remain high and she trade sideways w/more selling pressure or will more new hands accumulate and give her another little bump? Too much to speculate. The piece today reminding industry of the Sept iCDP conference they are participating in is just another yawner.

See a 200,000 block hit the sell side on level II. Looking like we'll begin to walk back down unless another mystery buyer shows up before the bell.

I looked at the trades on level II and I would agree that it didn't follow the typical pattern of oversold bounce. Folks have been waiting long enough for tangible news so that would be well received.

Hoping the 35% pop is based on a real catalyst and not just the dreaded dead cat bounce.

Also very aligned w/Steve's perspective on their lack of proven progress, secured IP, transparency, etc. They've had various delays, pipeline swap outs, leadership changes, etc since only '15. Many more are calling out the red flags, but some still sitting back assuming that this company is in "stealth mode" and "flying under the radar". Very unlikely.

Go back through historic reports from the company and you'll see a list of pipeline candidate changes. In just 2015 EB (INM-750/55) was a "secondary focus". This taken from their own presentation....."and also the ~$14 billion arthritis and joint disease market, where its leading candidate CTI-091 is nearing Phase 1 trials." Trials??? Here were the specific milestones in '15: 1) Skin penetration studies with cannabinoid-laden transdermal patch(Q2,2015)...2) in vivo studies with cannabinoid-laden transdermal patch (Q3,2015)...3) IP filing on cannabinoid-laden transdermal patch (Q3, 2015)..4) Initiate Phase I clinical trials (Q4, 2015)..5) Report clinical trial results to Health Canada and apply for NOC (Q1, 2016). That's quite the detailed list of milestones that simply disappeared.

Even better, here was the report on INM-085 (glaucoma) in '15. "Initial results from the preclinical trials for CTI-085 are extremely encouraging, and the company is anticipating initiating Phase 1 clinical trials during Q4 2015." I'd say we're just a tad delayed in our glaucoma trials. Matter of fact they barely ever mention this program at all anymore. How about this statement..."By the end of next year (2016) InMed should have ~11 therapies of its own in the pipeline. Folks are we close yet??? This is the thing about biotechs. Many have incredible visions that die on the vine. 85-95% burn cash until the lights go off.

He doesn't have to "feed" anything. It's been a pessimistic buffet and shareholders have been eating from its trough since Dec '17.

I was not personally impressed w/Blacher, but as you said maybe he was the smart one and bailed in the face of a dream unrealized. I mean the near-term prospects are looking bleaker by the day. The '20 warrants are down over 400% since the start of the summer. Clearly smart $$ isn't banking on revenues any time soon.

People get so excited over an executive bio. All exec bios are going to be glittery. People making wild assumptions of what someone will do based on a bio. Also all these assumptions about Blacher. Saying he couldn't have bailed for a better opportunity even though that's what EA said himself. People saying no EA is lying and Blacher was fired. I just don't know where people come up with these fabrications. Also, the advisory board. They lose a Hossain and some say well he was just a limited capacity advisor now, but then add EA's buddy Sazdanoff and somehow she's going to provide this amazing trajectory to the biz.

Not you HB. Other praise being showered by some over non-events.

People get so excited over the darnedest little things. Are the only buyers the FB group?

It's possible. Sazzad Hossain was just placed (from active CSO) into a Strategic Advisory role in January and now he's been totally scrubbed from the website. First, Ado Mohammed left, then Hossain, then Patterson and perhaps now Mancini?

When exactly does this grounded shuttle take off again?

Well missing milestones is never the plan, but it happens regularly in biotech and they've already been victim to delays. Insider buying is a good indicator of confidence, however Adams sold 1 mil shares and only bought 100k back.

If they can't get into revenues prior to the exhaustion of cash reserves it will take adding another 40 million shares at the current SP just to raise the same ~10 mil (USD) that was brought in from the Eight Capital bought deal. Any new institutional investor will demand a nice discount to current common share pricing which @ today's levels could easily make that 50 million or more additional dilutive shares added to raise that same 10 mil USD. Some of FB day dreamers like Swanson don't believe in dilution, but if InMed needs a cash injection while trading close to these levels be dam* sure the dilution will come and it will come at a very steep price to the retail investors.